Zura Bio (NASDAQ:ZURA) Upgraded at Leerink Partnrs

Leerink Partnrs upgraded shares of Zura Bio (NASDAQ:ZURA) to a strong-buy rating in a report published on Sunday,Zacks.com reports.

Other equities research analysts have also recently issued reports about the stock. HC Wainwright reduced their target price on shares of Zura Bio from $3.00 to $2.00 and set a “neutral” rating for the company in a report on Tuesday, August 19th. Wall Street Zen cut Zura Bio from a “hold” rating to a “sell” rating in a research report on Sunday, November 16th. Oppenheimer reduced their price objective on Zura Bio from $17.00 to $16.00 and set an “outperform” rating for the company in a research note on Friday, August 15th. Chardan Capital reaffirmed a “buy” rating and set a $10.00 price objective on shares of Zura Bio in a research report on Friday, November 14th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Zura Bio in a research note on Tuesday, October 14th. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $10.75.

Zura Bio Trading Up 0.3%

ZURA stock opened at $3.75 on Friday. The company has a market capitalization of $243.83 million, a P/E ratio of -5.77 and a beta of 0.24. Zura Bio has a twelve month low of $0.97 and a twelve month high of $4.68. The business has a 50 day simple moving average of $3.54 and a 200-day simple moving average of $2.19.

Zura Bio (NASDAQ:ZURA) last announced its earnings results on Thursday, November 13th. The company reported ($0.21) EPS for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.02). Research analysts predict that Zura Bio will post -0.65 EPS for the current fiscal year.

Hedge Funds Weigh In On Zura Bio

A number of large investors have recently modified their holdings of ZURA. Savant Capital LLC lifted its holdings in shares of Zura Bio by 190.4% in the 2nd quarter. Savant Capital LLC now owns 32,409 shares of the company’s stock valued at $34,000 after buying an additional 21,249 shares during the period. Scientech Research LLC purchased a new position in Zura Bio in the third quarter worth $45,000. AQR Capital Management LLC purchased a new position in Zura Bio in the first quarter worth $72,000. Nuveen LLC acquired a new stake in Zura Bio in the first quarter valued at $76,000. Finally, Forefront Wealth Partners LLC purchased a new stake in shares of Zura Bio during the 3rd quarter worth $93,000. 61.14% of the stock is owned by hedge funds and other institutional investors.

Zura Bio Company Profile

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.